Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora? (Q39017623)

8 September 2017

Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora? (English)

1 reference

inflammatory bowel diseases

8 September 2017

0 references

4

Nathalie Chaput

0 references

Caroline Robert

7

object named as

Caroline Robert

0 references

Patricia Lepage

object named as

Patricia Lepage

6

0 references

author name string

Franck Carbonnel

1

1 reference

8 September 2017

Emilie Soularue

2

1 reference

8 September 2017

Clélia Coutzac

3

1 reference

8 September 2017

Christine Mateus

5

1 reference

8 September 2017

16 January 2017

1 reference

Seminars in Immunopathology

8 September 2017

1 reference

8 September 2017

39

1 reference

8 September 2017

3

1 reference

8 September 2017

327-331

1 reference

https://scigraph.springernature.com/pub.10.1007/s00281-016-0613-x

8 September 2017

0 references

cites work

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Management of immune-related adverse events and kinetics of response with ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Systematic review: colitis associated with anti-CTLA-4 therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Pembrolizumab versus Ipilimumab in Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Abatacept for Crohn's disease and ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

B70 antigen is a second ligand for CTLA-4 and CD28.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

The role of CTLA-4 in the regulation of T cell immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Cutting edge: cell-extrinsic immune regulation by CTLA-4 expressed on conventional T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Immune Checkpoint Blockade in Cancer Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

CTLA-4 promotes Foxp3 induction and regulatory T cell accumulation in the intestinal lamina propria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Peripheral education of the immune system by colonic commensal microbiota.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Early-onset Crohn's disease and autoimmunity associated with a variant in CTLA-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Reciprocal interactions of the intestinal microbiota and immune system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

T helper 1 and T helper 2 cells are pathogenic in an antigen-specific model of colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: increased T helper cell type 1 response and ability to transfer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Relevance of serologic studies in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Commensal-Specific CD4(+) Cells From Patients With Crohn's Disease Have a T-Helper 17 Inflammatory Profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-016-0613-X

The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28093620

12 December 2020

inferred from PubMed ID database lookup

Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28093620

12 December 2020

inferred from PubMed ID database lookup

Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28093620

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1007/S00281-016-0613-X

1 reference

release_l76z6pckyrctlnwons26d7ygpe

8 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/l76z6pckyrctlnwons26d7ygpe

24 November 2022

mapped directly with Wikidata item

1 reference